Thrombin-activable Fibrinolysis Inhibitor (TAFI) Zymogen Is an Active Carboxypeptidase

This publication has 31 references indexed in Scilit:

• Post-translational Modifications of Human Thrombin-Activatable Fibrinolysis Inhibitor (TAFI): Evidence for a Large Shift in the Isoelectric Point and Reduced Solubility upon Activation
  Biochemistry, 2006
• Thrombin-Activatable Fibrinolysis Inhibitor
  Current Medicinal Chemistry, 2004
• Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis
  Immunological Reviews, 2001
• Immunological Assay for the Determination of Procarboxypeptidase U Antigen Levels in Human Plasma
  Thrombosis and Haemostasis, 2001
• Inactivation of Active Thrombin-activable Fibrinolysis Inhibitor Takes Place by a Process That Involves Conformational Instability Rather Than Proteolytic Cleavage
  Journal of Biological Chemistry, 2000
• Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor
  Journal of Biological Chemistry, 2000
• TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex
  Published by Elsevier ,1996
• Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor
  Journal of Biological Chemistry, 1995
• Purification and characterization of a new arginine carboxypeptidase in human serum
  Biochimica et Biophysica Acta (BBA) - General Subjects, 1990
• An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits
  Biochemical and Biophysical Research Communications, 1989